Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2

9 Mar 2020

Abstract excerpt

PURPOSE: We analyzed whole transcriptome sequencing in tumors from 23 patients with stage III or IV melanoma from a pilot trial of the anti-GD2 immunocytokine, hu14.18-IL2, to identify predictive immune and/or tumor biomarkers in patients with melanoma at high risk for recurrence. EXPERIMENTAL DESIGN: Patients were randomly assigned to receive the first of three monthly courses of hu14.18-IL2 immunotherapy either...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cutaneous Melanoma Detection and Management
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32152202
DOI: 10.1158/1078-0432.ccr-19-3294

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2PMID 32152202Read ↗

Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma PatientsSemantic proximity Read ↗

Tumor immunogenomic signatures improve a prognostic model of melanoma survival.Semantic proximity Read ↗

Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With CancerSemantic proximity Read ↗

Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic MelanomaSemantic proximity Read ↗

Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.Semantic proximity Read ↗

Predicting Clinical Outcome through Molecular Profiling in Stage III MelanomaSemantic proximity Read ↗

Melanoma MicroRNA Signature Predicts Post-Recurrence SurvivalSemantic proximity Read ↗

Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.Semantic proximity Read ↗

Serum‐based miRNAs in the prediction and detection of recurrence in melanoma patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.